Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged ≥1 to <7 years with NF1-related Symptomatic, Inoperable PN

Trial Identifier: D1346C00004
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp.
Start Date: January 2022
Primary Completion Date: November 2027
Study Completion Date: April 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Hamburg, Germany, 20246
Germany Munchen, Germany, 80337
Germany Tubingen, Germany, 72076
Italy Milan, Italy, 20133
Italy Rome, Italy, 00165
Japan Nagoya, Japan, 466-8560
Japan Setagaya, Japan, 157-8535
Netherlands Rotterdam, Netherlands, 3015 GD
Russia Moscow, Russia, 125412
Russia Moscow, Russia, 119620
Spain Barcelona, Spain, 08950
Spain Madrid, Spain
USA, Ohio Akron, Ohio, USA, 44308
USA, Pennsylvania Philadelphia, Pennsylvania, USA, 19104
USA, Texas Houston, Texas, USA, 77030
USA, Virginia Richmond, Virginia, USA, 23219